Improved candidate drug mining for Alzheimer's disease.
Yu-Huei ChengLi-Yeh ChuangHsueh-Wei ChangCheng-Hong YangPublished in: BioMed research international (2014)
Alzheimer's disease (AD) is the main cause of dementia for older people. Although several antidementia drugs such as donepezil, rivastigmine, galantamine, and memantine have been developed, the effectiveness of AD drug therapy is still far from satisfactory. Recently, the single nucleotide polymorphisms (SNPs) have been chosen as one of the personalized medicine markers. Many pharmacogenomics databases have been developed to provide comprehensive information by associating SNPs with drug responses, disease incidence, and genes that are critical in choosing personalized therapy. However, we found that some information from different sets of pharmacogenomics databases is not sufficient and this may limit the potential functions for pharmacogenomics. To address this problem, we used approximate string matching method and data mining approach to improve the searching of pharmacogenomics database. After computation, we can successfully identify more genes linked to AD and AD-related drugs than previous online searching. These improvements may help to improve the pharmacogenomics of AD for personalized medicine.
Keyphrases
- adverse drug
- genome wide
- clinical decision support
- drug induced
- health information
- big data
- cognitive decline
- randomized controlled trial
- emergency department
- systematic review
- mild cognitive impairment
- risk factors
- dna methylation
- stem cells
- gene expression
- mesenchymal stem cells
- machine learning
- cell therapy
- transcription factor